IL227097B - Combination comprising a proteasome inhibiting compound and an akt inhibitor, kit comprising same and use thereof for treating cancer - Google Patents
Combination comprising a proteasome inhibiting compound and an akt inhibitor, kit comprising same and use thereof for treating cancerInfo
- Publication number
- IL227097B IL227097B IL227097A IL22709713A IL227097B IL 227097 B IL227097 B IL 227097B IL 227097 A IL227097 A IL 227097A IL 22709713 A IL22709713 A IL 22709713A IL 227097 B IL227097 B IL 227097B
- Authority
- IL
- Israel
- Prior art keywords
- kit
- combination
- same
- treating cancer
- inhibiting compound
- Prior art date
Links
- 229940126638 Akt inhibitor Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 title 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000003197 protein kinase B inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161431508P | 2011-01-11 | 2011-01-11 | |
| PCT/US2012/020863 WO2012097021A1 (en) | 2011-01-11 | 2012-01-11 | Combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL227097B true IL227097B (en) | 2018-02-28 |
Family
ID=46507420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL227097A IL227097B (en) | 2011-01-11 | 2013-06-20 | Combination comprising a proteasome inhibiting compound and an akt inhibitor, kit comprising same and use thereof for treating cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US20130288984A1 (OSRAM) |
| EP (1) | EP2663189B1 (OSRAM) |
| JP (1) | JP6100700B2 (OSRAM) |
| KR (1) | KR20140053836A (OSRAM) |
| CN (1) | CN103298345B (OSRAM) |
| AU (1) | AU2012205601B2 (OSRAM) |
| BR (1) | BR112013017722A2 (OSRAM) |
| CA (1) | CA2824201A1 (OSRAM) |
| EA (1) | EA029000B1 (OSRAM) |
| ES (1) | ES2689760T3 (OSRAM) |
| IL (1) | IL227097B (OSRAM) |
| MX (1) | MX356704B (OSRAM) |
| SG (2) | SG10201600077RA (OSRAM) |
| WO (1) | WO2012097021A1 (OSRAM) |
| ZA (1) | ZA201304139B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015049649A1 (en) * | 2013-10-01 | 2015-04-09 | Gbglaxosmithkline Intellectual Property (No.2) Limited | Combination |
| CA2929715A1 (en) * | 2013-11-07 | 2015-05-14 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie2 kinase useful in the treatment of cancer |
| WO2019152711A1 (en) | 2018-01-31 | 2019-08-08 | Diciphera Pharmaceuticals Llc. | Combination therapy for the treatment of gastrointestinal stromal tumors |
| KR102708050B1 (ko) | 2018-01-31 | 2024-09-24 | 데시페라 파마슈티칼스, 엘엘씨. | 비만 세포증의 치료를 위한 병용 요법 |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| CA3150433A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| FI4084778T3 (fi) | 2019-12-30 | 2023-12-18 | Deciphera Pharmaceuticals Llc | Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi |
| CN115243681B (zh) | 2019-12-30 | 2024-08-16 | 德西费拉制药有限责任公司 | 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物 |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6328590B1 (en) | 2000-07-20 | 2001-12-11 | Emc Corporation | Methods and apparatus for controlling attachment of an electronic module with a circuit board connector |
| ES2551293T3 (es) * | 2004-03-24 | 2015-11-17 | Abbvie Inc. | Inhibidores de quinasas de pirazol tricíclicos |
| JP4937129B2 (ja) | 2004-10-13 | 2012-05-23 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | ３−［５−クロロ−４−［（２，４−ジフルオロベンジル）オキシ］−６−オキソピリミジン−１（６ｈ）−イル］−ｎ−（２−ヒドロキシエチル）−４−メチルベンズアミドの結晶形 |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| US7678363B2 (en) * | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| EP1840114A1 (en) | 2006-03-30 | 2007-10-03 | LTB4 Sweden AB | Crystalline Leukotriene B4 |
| AU2007234379A1 (en) | 2006-04-05 | 2007-10-11 | Novartis Ag. | Combinations of therapeutic agents for treating cancer |
| WO2007122686A1 (ja) | 2006-04-14 | 2007-11-01 | Eisai R & D Management Co., Ltd. | ベンズイミダゾール化合物 |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| RS52956B (sr) | 2006-08-25 | 2014-02-28 | Janssen Oncology Inc. | Kompozicije za tretman kancera |
| JP4299327B2 (ja) | 2006-08-31 | 2009-07-22 | トヨタ自動車株式会社 | 可変バルブタイミング装置 |
| WO2008094321A2 (en) * | 2006-10-04 | 2008-08-07 | Universtiy Of South Florida | Akt sensitization of cancer cells |
| MY149140A (en) | 2006-10-13 | 2013-07-15 | Basf Se | Hydrates of 2-chloro 5-y3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoro-methyl)-1-(2h)-pyrimidinyl"-4-fluoro-n- yymethyl-(1-methylethyl)-amino"sulphonyl"benzamide |
| AR064010A1 (es) * | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| NZ585261A (en) | 2007-10-11 | 2011-10-28 | Astrazeneca Ab | Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors |
| WO2009067453A1 (en) * | 2007-11-19 | 2009-05-28 | Syndax Pharmaceuticals, Inc. | Combinations of hdac inhibitors and proteasome inhibitors |
| DE102008044901A1 (de) | 2008-08-29 | 2010-03-04 | Siemens Aktiengesellschaft | Verfahren und Vorrichtung zur Auswahl eines Bestrahlungsplans sowie Bestrahlungsanlage |
| MX2011008073A (es) * | 2009-01-30 | 2011-11-18 | Glaxosmithkline Llc | Hidrocloruro de n-{(1-s)-2-amino -1-[(3-fluorofenil)metil]etil}-5- cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino. |
| WO2010149755A1 (en) | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
| US8796298B2 (en) | 2009-10-08 | 2014-08-05 | Glaxosmithkline Llc | Combination of a B-Raf inhibitor: N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1- dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and the Akt inhibitor: N-{ (1S)-2-amino-1-[(3- fluorophenyl)methyl]ethyl}-5-chIoro-4-(4-chIoro- 1 -methyl- 1 H-pyrazol-5-yl)-2-10 thiophenecarboxamide useful in the treatment of cancer |
| ES2620644T3 (es) | 2011-04-01 | 2017-06-29 | Genentech, Inc. | Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso |
| CA2834850A1 (en) | 2011-05-03 | 2012-11-08 | University Of Rochester | Methods for treating prostate cancer |
| EA201490265A1 (ru) | 2011-07-13 | 2014-12-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| CA2851330C (en) | 2011-10-10 | 2019-07-16 | Zach System | Process for preparing 17-substituted steroids |
| PT2785349T (pt) | 2011-11-30 | 2019-12-11 | Astrazeneca Ab | Tratamento combinado de cancro |
| KR20250151610A (ko) | 2012-06-04 | 2025-10-21 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| US20160235714A1 (en) | 2013-10-01 | 2016-08-18 | Novartis Ag | Enzalutamide in combination with afuresertib for the treatment of cancer |
-
2012
- 2012-01-11 SG SG10201600077RA patent/SG10201600077RA/en unknown
- 2012-01-11 KR KR1020137021098A patent/KR20140053836A/ko not_active Abandoned
- 2012-01-11 CA CA2824201A patent/CA2824201A1/en not_active Abandoned
- 2012-01-11 BR BR112013017722A patent/BR112013017722A2/pt not_active IP Right Cessation
- 2012-01-11 ES ES12733916.6T patent/ES2689760T3/es active Active
- 2012-01-11 US US13/978,765 patent/US20130288984A1/en not_active Abandoned
- 2012-01-11 EP EP12733916.6A patent/EP2663189B1/en active Active
- 2012-01-11 EA EA201391027A patent/EA029000B1/ru not_active IP Right Cessation
- 2012-01-11 AU AU2012205601A patent/AU2012205601B2/en not_active Ceased
- 2012-01-11 SG SG2013043856A patent/SG191724A1/en unknown
- 2012-01-11 WO PCT/US2012/020863 patent/WO2012097021A1/en not_active Ceased
- 2012-01-11 JP JP2013549503A patent/JP6100700B2/ja active Active
- 2012-01-11 CN CN201280004830.0A patent/CN103298345B/zh active Active
- 2012-01-11 MX MX2013008074A patent/MX356704B/es active IP Right Grant
- 2012-02-08 US US13/368,434 patent/US20120258933A1/en not_active Abandoned
-
2013
- 2013-06-06 ZA ZA2013/04139A patent/ZA201304139B/en unknown
- 2013-06-20 IL IL227097A patent/IL227097B/en active IP Right Grant
-
2015
- 2015-01-06 US US14/590,143 patent/US20150119337A1/en not_active Abandoned
- 2015-08-20 US US14/831,261 patent/US20160022641A1/en not_active Abandoned
-
2016
- 2016-09-08 US US15/259,694 patent/US20160375086A1/en not_active Abandoned
- 2016-12-20 US US15/385,205 patent/US10449226B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2824201A1 (en) | 2012-07-19 |
| WO2012097021A1 (en) | 2012-07-19 |
| MX2013008074A (es) | 2013-08-09 |
| AU2012205601A1 (en) | 2013-08-01 |
| US20160022641A1 (en) | 2016-01-28 |
| JP2014507412A (ja) | 2014-03-27 |
| AU2012205601B2 (en) | 2016-03-24 |
| ZA201304139B (en) | 2014-02-26 |
| US20150119337A1 (en) | 2015-04-30 |
| EP2663189B1 (en) | 2018-07-04 |
| US20160375086A1 (en) | 2016-12-29 |
| CN103298345A (zh) | 2013-09-11 |
| SG10201600077RA (en) | 2016-02-26 |
| EP2663189A4 (en) | 2014-06-11 |
| US20170100449A1 (en) | 2017-04-13 |
| US20120258933A1 (en) | 2012-10-11 |
| KR20140053836A (ko) | 2014-05-08 |
| US20130288984A1 (en) | 2013-10-31 |
| MX356704B (es) | 2018-06-11 |
| EP2663189A1 (en) | 2013-11-20 |
| ES2689760T3 (es) | 2018-11-15 |
| CN103298345B (zh) | 2016-12-14 |
| EA201391027A1 (ru) | 2014-01-30 |
| BR112013017722A2 (pt) | 2016-07-12 |
| SG191724A1 (en) | 2013-08-30 |
| JP6100700B2 (ja) | 2017-03-22 |
| US10449226B2 (en) | 2019-10-22 |
| EA029000B1 (ru) | 2018-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273079B (en) | Heterocycloamines as pi3k inhibitors | |
| IL227097B (en) | Combination comprising a proteasome inhibiting compound and an akt inhibitor, kit comprising same and use thereof for treating cancer | |
| ZA201308062B (en) | Combinations of akt inhibitor compounds and erlotinib, and methods of use | |
| HUE060305T2 (hu) | FAP-aktivált proteaszóma inhibitorok a szolid tumorok kezelésére | |
| EP2663312A4 (en) | IRAQ INHIBITORS AND THEIR USE | |
| AP2013006680A0 (en) | Methods and compounds for treating paramyxoviridaevirus infections | |
| IL230917A (en) | 1dyrk inhibitors and their uses | |
| AP3597A (en) | Imidazopyridazines as akt kinase inhibitors | |
| ZA201201992B (en) | Met inhibitors for enhancing radiotherapy efficacy | |
| IL228643A0 (en) | Combinations of akt and mek inhibitor compounds, and methods of use | |
| ZA201306074B (en) | Cathepsin c inhibitors | |
| PL2519231T3 (pl) | Inhibitory proteasomów do leczenia raka | |
| HK1187784A (en) | Cathepsin c inhibitors | |
| GB201004308D0 (en) | New inhibitor compounds | |
| GB201018597D0 (en) | Inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |